AstraZeneca Invests $200 Million For Manufacturing Plant In China Medical City
This article was originally published in PharmAsia News
AstraZeneca PLC has announced a plan to invest $200 million to build a new manufacturing plant inside Taizhou, Jiangsu-based China Medical City
You may also be interested in...
Reporting 32% growth in China for 2012, BI will be the first Big Pharma to enter the biologics contract manufacturing space in the country.
Roche’s surging growth in China could hint at what’s coming to AstraZeneca in emerging markets as Pascal Soriot, Roche’s head of pharmaceuticals, takes over at AZ.
AstraZeneca Hints At Acquisitions, Merck And Novo Nordisk React To China Cuts – Emerging Market Earnings Roundup (Part 3)
AstraZeneca plans to enhance capacity in emerging markets while cutting jobs and consolidating operations. Merck sees strong volume growth in China, and Novo Nordisk reports a slow quarterly sales growth in the Chinese human insulin market.